Genfit
Develops drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases.
Launch date
Employees
Market cap
AUD320m
Enterprise valuation
AUD307m (Public information from Sep 2024)
Share price
$4.19 GNFT
Company register number 424341907
Loos Hauts-de-France (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 80.1m | 20.2m | 28.6m | 82.5m | 48.5m | 97.5m |
| % growth | (98 %) | 10367 % | (75 %) | 41 % | 189 % | (41 %) | 101 % |
| EBITDA | (67.5m) | 79.5m | (17.3m) | (22.3m) | 29.4m | 2.7m | 12.1m |
| % EBITDA margin | (8822 %) | 99 % | (85 %) | (78 %) | 36 % | 6 % | 12 % |
| Profit | (101m) | 67.3m | (23.7m) | (28.9m) | 28.4m | (22.3m) | 22.9m |
| % profit margin | (13232 %) | 84 % | (117 %) | (101 %) | 34 % | (46 %) | 23 % |
| EV / revenue | 221.7x | 0.4x | 6.5x | 5.9x | 2.3x | 3.4x | 1.6x |
| EV / EBITDA | -2.5x | 0.4x | -7.6x | -7.5x | 6.6x | 60.1x | 12.8x |
| R&D budget | 59.1m | 35.2m | 35.8m | 46.7m | - | - | - |
| R&D % of revenue | 7725 % | 44 % | 177 % | 164 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Growth Equity VC | ||
| N/A | €7.1m | Early VC | |
* | $18.5m | Post IPO Equity | |
| N/A | €21.0m | Post IPO Equity | |
* | N/A | €33.9m | Growth Equity VC |
| N/A | $135m Valuation: $768m 9423.4x EV/LTM Revenues -9.7x EV/LTM EBITDA | IPO | |
| Total Funding | AUD69.7m | ||
